Novo Nordisk has partnered with Indian pharma giant Emcure to commercialise Poviztra (commercial brand name for weight loss drug semaglutide) injection in India. The pharma companies announced this partnership on November 10.
Under this partnership, Emcure pharmaceuticals would become the first Indian company to secure exclusive distribution rights for Poviztra (semaglutide injection 2.4 mg), a second brand of the weight loss drug Wegovy.
Emcure partnership aimed to boost distribution
Emcure in its press release said the collaboration is aimed to strengthen the distribution and marketing of semaglutide for weight loss. The partnership will focus on expanding the distribution and marketing of semaglutide for weight loss, particularly through pharmacies in regions of the country beyond those currently served by Novo Nordisk. Emcure will focus on expanding the distribution of Wegovy through pharmacies. Wegovy (semaglutide injection 2.4 mg) was launched in India in June 2025.
As a part of the agreement between both the companies, Emcure will be the exclusive distributor of Povitzra. The Indian company will be responsible for managing the commercialisation and marketing of the weight loss drug.
Obesity a key concern, says Novo Nordisk
Commenting on the partnership, Jay Thyagarajan, Senior Vice President, Region APAC, Novo Nordisk said, “Obesity is a serious chronic disease affecting millions of people across India and results in significant unmet medical needs. Recognising the magnitude of the obesity challenge, we launched Wegovy in India a few months ago. Now, we are happy to join hands with Emcure Pharma to broaden access to high-quality, safe, and effective obesity treatment.”
“We are thrilled to partner with Novo Nordisk India to bring Poviztra to India and are proud to be the first Indian pharmaceutical company to bring the world’s most widely used and trusted GLP-1- based weight loss molecule to the Indian market”, Satish Mehta, Chief Executive Officer and Managing Director, Emcure Pharma added.
About Poviztra (second brand name Wegovy)
Poviztra /Wegovy (semaglutide injection 2.4 mg) is used with as a supplement with a reduced-calorie diet and regular physical activity for weight management in adults with a BMI of 30 kg/m² or higher, or 27 kg/m² or higher with at least one weight-related condition. It is also indicated to reduce the risk of major cardiovascular events in adults with established cardiovascular disease who are overweight or obese. The injection is taken once a week using a pen device available in five doses — 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and a maintenance dose of 2.4 mg.
Share Price
The share price of Emcure Pharma is trading 7% higher in the intraday session today. Over the last five trading sessions, the company’s stock has delivered a return of around 10%.
